Table 2. Univariate and multivariate analysis of LNM in HNSCC based on clinicopathological characteristics.
| Clinicopathological characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| P value (χ2/t)† | OR (95% CI) | P value | ||
| Age groups | 0.63 | |||
| Sex | 0.23 | |||
| Primary subsite | 0.19 | |||
| Smoking | 0.42 | |||
| Alcohol, yes vs. no (ref) | 0.002* | 2.915 (1.349–6.298) | 0.006* | |
| Diabetes | 0.18 | |||
| Hypertension | 0.65 | |||
| cT staging | 0.49 | |||
| Ki-67 (%) | 0.004* | 1.031 (1.006–1.056) | 0.01* | |
| p53 | 0.12 | |||
| p16 | 0.11 | |||
| F. nucleatum enrichment, high vs. low (ref) | 0.006* | 2.759 (1.077–7.069) | 0.03* | |
| IL-32 expression | 0.002* | 1.331 (1.030–1.720) | 0.03* | |
†, comparisons performed using Chi-square test for categorical variables and Student’s t-test for continuous variables. All Student’s t-tests and Chi-square tests were two-sided. *, indicates significant P values <0.05. cT staging, clinical T staging, according to AJCC 8th; HNSCC, head and neck squamous cell carcinoma; F. nucleatum, Fusobacterium nucleatum; Ki-67, antigen Kiel 67; LNM, lymph node metastasis; p53, tumor protein p53; p16 (P16INK4; CDKN2A), cyclin dependent kinase inhibitor 2A; CI, confidence interval; OR, odds ratio.